SCHEMBL6822095

SCHEMBL6822095

COc1ccn2nc(-c3ccc(F)cc3)c(-c3ccc(S(=O)(=O)c4ccccc4)nn3)c2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.37
PTGS2 P35354 7/20 0.37
AURKA O14965 1/20 0.36
EGFR P00533 1/20 0.36
RAF1 P04049 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
GSK3B P49841 1/20 0.36
PTGS1 P23219 1/20 0.36
HSP90AA1 P07900 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 2/20 0.35
HTT P42858 2/20 0.35
MITF O75030 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6818747 0.93 AURKA (0.39) MAPK14PTGDR2AURKAMEN1KMT2A
SCHEMBL6822357 0.87 NPC1 (0.35) AURKAMEN1KMT2ALMNAMAPT
SCHEMBL7367472 0.79 KDM4E (0.39) MAPK14AURKAMEN1KMT2AALDH1A1
SCHEMBL6821442 0.77 HTR6 (0.37) MAPK14PTGS2AURKAMEN1KMT2A
SCHEMBL7296061 0.77 IGF1R (0.51) MAPK14PTGS2EGFRRAF1ADORA3
SCHEMBL7364009 0.77 LMNA (0.37) PTGS2PTGS1ALDH1A1LMNAHTT
SCHEMBL6822166 0.75 MAPK14 (0.44) MAPK14PTGS2EGFRRAF1ADORA3
SCHEMBL6824619 0.74 LMNA (0.46) MAPK14PTGS2EGFRRAF1ADORA3
SCHEMBL7373754 0.74 IGF1R (0.39) MAPK14PTGDR2PTGS2AURKAEGFR
SCHEMBL6818465 0.72 MAPK14 (0.42) MAPK14PTGS2EGFRRAF1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof ADRB1, ADRA1D, ADRB3 MAPK14 3737/4885PTGDR2 216/4885PTGS2 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.